AngioDynamics Affirms FY2026 Adj EPS Guidance of $(0.33)-$(0.23) vs $(0.33) Est; Raises FY2026 Sales Guidance from $308M-$313M to $312M-$314M vs $310.204M Est

Fiscal Year 2026 Financial Guidance

For fiscal year 2026 the company now expects:

Guidance Metric		Guidance Action		Current Guidance (as of January 6, 2026)		Previous Guidance (as of October 2, 2025)
Net Sales		Increased		$312 - $314 million		$308 - $313 million
Med Tech Net Sales Growth		Unchanged		14% - 16%		14% - 16%
Med Device Net Sales Growth		Increased		0% - 1%		Flat
Gross Margin		Unchanged		53.5% - 55.5%		53.5% - 55.5%
Adjusted EBITDA		Increased		$8.0 - $10.0 M		$6.0 - $10.0 million
Adjusted EPS		Unchanged		($0.33) – ($0.23)		($0.33) – ($0.23)
Free Cash Flow		Unchanged		Positive for full year FY 2026		Positive for full year FY 2026

Tariff Related Guidance Assumptions

For the full fiscal year 2026, the company continues to expect a $4.0 - $6.0 million impact from tariffs, which are included in the above provided guidance.